Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
22M
-
Shares change
-
+894K
-
Total reported value, excl. options
-
$132M
-
Value change
-
+$5.19M
-
Put/Call ratio
-
1.56
-
Number of buys
-
37
-
Number of sells
-
-39
-
Price
-
$6.01
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q4 2021
105 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q4 2021.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22M shares
of 66.6M outstanding shares and own 33.07% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (3.52M shares), BlackRock Inc. (2.53M shares), CAXTON CORP (2.52M shares), VANGUARD GROUP INC (1.96M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.67M shares), Octagon Capital Advisors LP (983K shares), Artal Group S.A. (750K shares), STATE STREET CORP (693K shares), TWO SIGMA ADVISERS, LP (665K shares), and GEODE CAPITAL MANAGEMENT, LLC (645K shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.